These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 9250234)

  • 1. Isoniazid preventive therapy in human immunodeficiency virus-infected persons. Long-term effect on development of tuberculosis and survival.
    Moreno S; Miralles P; Diaz MD; Baraia J; Padilla B; Berenguer J; Alberdi JC
    Arch Intern Med; 1997 Aug 11-25; 157(15):1729-34. PubMed ID: 9250234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease.
    Graham NM; Galai N; Nelson KE; Astemborski J; Bonds M; Rizzo RT; Sheeley L; Vlahov D
    Arch Intern Med; 1996 Apr; 156(8):889-94. PubMed ID: 8774208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for development of tuberculosis after isoniazid chemoprophylaxis in human immunodeficiency virus-infected patients.
    Casado JL; Moreno S; Fortún J; Antela A; Quereda C; Navas E; Moreno A; Dronda F
    Clin Infect Dis; 2002 Feb; 34(3):386-9. PubMed ID: 11753825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre.
    Aisu T; Raviglione MC; van Praag E; Eriki P; Narain JP; Barugahare L; Tembo G; McFarland D; Engwau FA
    AIDS; 1995 Mar; 9(3):267-73. PubMed ID: 7755915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active tuberculosis in individuals infected with human immunodeficiency virus after isoniazid prophylaxis.
    Fitzgerald DW; Morse MM; Pape JW; Johnson WD
    Clin Infect Dis; 2000 Dec; 31(6):1495-7. PubMed ID: 11096020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of the human immunodeficiency virus in the incidence of tuberculosis in a cohort of intravenous drug users: effectiveness of anti-tuberculosis chemoprophylaxis.
    Jansà JM; Serrano J; Caylà JA; Vidal R; Ocaña I; Español T
    Int J Tuberc Lung Dis; 1998 Feb; 2(2):140-6. PubMed ID: 9580481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS.
    Gordin FM; Matts JP; Miller C; Brown LS; Hafner R; John SL; Klein M; Vaughn A; Besch CL; Perez G; Szabo S; El-Sadr W
    N Engl J Med; 1997 Jul; 337(5):315-20. PubMed ID: 9233868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No evidence for multiple-drug prophylaxis for tuberculosis compared with isoniazid alone in Southeast Asian refugees and migrants: completion and compliance are major determinants of effectiveness.
    MacIntyre CR; Ansari MZ; Carnie J; Hart WG
    Prev Med; 2000 May; 30(5):425-32. PubMed ID: 10845752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of human immunodeficiency virus on response to treatment and recurrence rate in patients treated for tuberculosis: two-year follow-up of a cohort in Lusaka, Zambia.
    Elliott AM; Halwiindi B; Hayes RJ; Luo N; Mwinga AG; Tembo G; Machiels L; Steenbergen G; Pobee JO; Nunn PP
    J Trop Med Hyg; 1995 Feb; 98(1):9-21. PubMed ID: 7861484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of isoniazid prophylaxis on incidence of active tuberculosis among Thai HIV-infected individuals.
    Saenghirunvattana S
    J Med Assoc Thai; 1996 May; 79(5):285-7. PubMed ID: 8708519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival in a cohort of human immunodeficiency virus-infected tuberculosis patients in New York City. Implications for the expansion of the AIDS case definition.
    Stoneburner R; Laroche E; Prevots R; Singh T; Blum S; Terry P; Reatrice S; Adler J
    Arch Intern Med; 1992 Oct; 152(10):2033-7. PubMed ID: 1358042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
    Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
    East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long term follow up of HIV-infected patients with tuberculosis treated with 6-month intermittent short course chemotherapy.
    Swaminathan S; Deivanayagam CN; Rajasekaran S; Venkatesan P; Padmapriyadarsini C; Menon PA; Ponnuraja C; Dilip M
    Natl Med J India; 2008; 21(1):3-8. PubMed ID: 18472696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients.
    Pulido F; Peña JM; Rubio R; Moreno S; González J; Guijarro C; Costa JR; Vázquez JJ
    Arch Intern Med; 1997 Jan; 157(2):227-32. PubMed ID: 9009982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effectiveness of prophylaxis against tuberculosis in patients infected with HIV].
    Arbeláez MP; Arbeláez A; Gómez RD; Rojas C; Vélez L; Arias SL; Nagles J; Peláez LM; Betancourt G; Velásquez G
    Biomedica; 2007 Dec; 27(4):515-25. PubMed ID: 18320119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors and outcome of human immunodeficiency virus-infected patients with sporadic multidrug-resistant tuberculosis in New York City.
    Mannheimer SB; Sepkowitz KA; Stoeckle M; Friedman CR; Hafner A; Riley LW
    Int J Tuberc Lung Dis; 1997 Aug; 1(4):319-25. PubMed ID: 9432387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002-2005.
    Gupta A; Nayak U; Ram M; Bhosale R; Patil S; Basavraj A; Kakrani A; Philip S; Desai D; Sastry J; Bollinger RC;
    Clin Infect Dis; 2007 Jul; 45(2):241-9. PubMed ID: 17578786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Completion of isoniazid preventive therapy and survival in HIV-infected, TST-positive adults in Tanzania.
    Kabali C; von Reyn CF; Brooks DR; Waddell R; Mtei L; Bakari M; Matee M; Pallangyo K; Arbeit RD; Horsburgh CR
    Int J Tuberc Lung Dis; 2011 Nov; 15(11):1515-21, i. PubMed ID: 22008766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs.
    Scholten JN; Driver CR; Munsiff SS; Kaye K; Rubino MA; Gourevitch MN; Trim C; Amofa J; Seewald R; Highley E; Fujiwara PI
    Clin Infect Dis; 2003 Dec; 37(12):1686-92. PubMed ID: 14689352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of tuberculosis risk with the degree of tuberculin reaction in HIV-infected patients. The Gruppo Italiano di Studio Tubercolosi e AIDS.
    Girardi E; Antonucci G; Ippolito G; Raviglione MC; Rapiti E; Di Perri G; Babudieri S
    Arch Intern Med; 1997 Apr; 157(7):797-800. PubMed ID: 9125013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.